|1.||Horrobin, David F: 4 articles (11/2004 - 01/2002)|
|2.||Frangou, Sophia: 3 articles (04/2013 - 01/2006)|
|3.||McCrone, Paul: 2 articles (04/2013 - 01/2006)|
|4.||Puri, B K: 2 articles (09/2008 - 07/2005)|
|5.||Lewis, Michael: 2 articles (06/2007 - 01/2006)|
|6.||Murck, Harald: 2 articles (04/2007 - 05/2006)|
|7.||Emsley, Robin: 2 articles (05/2006 - 09/2002)|
|8.||Horrobin, D F: 2 articles (07/2005 - 06/2004)|
|9.||Craufurd, David: 1 article (09/2015)|
|10.||Landwehrmeyer, Bernhard: 1 article (09/2015)|
|1.||Huntington Disease (Huntington's Disease)
12/01/2008 - "Ethyl-EPA was not beneficial in patients with Huntington disease during 6 months of placebo-controlled evaluation. "
01/21/2002 - "After 6 months all the patients treated with ethyl-EPA improved on the orofacial component of the Unified Huntington's Disease Rating Scale while all the patients on placebo deteriorated on this scale (p < 0.03). "
01/21/2002 - "MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment."
12/01/2008 - "Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study."
09/01/2008 - "High-resolution cerebral magnetic resonance imaging scans were acquired at baseline, 6 months and 1 year in up to 34 patients with stage I or II Huntington's disease who took part in a randomized, double-blind, placebo-controlled trial of ethyl-EPA. "
|2.||Schizophrenia (Dementia Praecox)
12/01/2001 - "For schizophrenia patients treated with 3 g/day of ethyl EPA, improvement in residual symptoms and cognitive impairment was no greater than for schizophrenia patients treated with placebo."
03/01/2011 - "Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study."
09/01/2002 - "The study investigated the efficacy and tolerability of ethyl-eicosapentaenoic acid (E-EPA) as add-on treatment in chronic, severe schizophrenia. "
09/01/2002 - "Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia."
12/01/2001 - "A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia."
|3.||Bipolar Disorder (Mania)
01/01/2006 - "Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study."
04/01/2013 - "Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder."
08/01/2006 - "Ethyl-eicosapentaenoic acid in bipolar depression."
01/01/2006 - "Adjunctive ethyl-EPA is an effective and well-tolerated intervention in bipolar depression."
01/01/2006 - "In a12-week, double-blind study individuals with bipolar depression were randomly assigned to adjunctive treatment with placebo (n=26) or with 1 g/day (n=24) or 2 g/day (n=25) of ethyl-EPA. "
|5.||Borderline Personality Disorder (Personality Disorders, Borderline)
|2.||ethyl eicosapentaenoic acid
|3.||eicosapentaenoic acid ethyl ester
|5.||Antipsychotic Agents (Antipsychotics)